Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04009122Not ApplicableCompleted

Evaluation of the Quality of Life of Patients With Metastatic Non-small Cell Lung Cancer With Supplementary Therapy With IGEN-0206

Role: lead

NCT05391074Not ApplicableUnknown

Oral Postbiotics in Patients With Macular Atrophy

Role: collaborator

NCT05056025Not ApplicableUnknown

Study to Evaluate the Response to Supplementation With Postbiotics in Patients With Macular Degeneration.

Role: collaborator

All 3 trials loaded